WO2021154188A1 - Pharmaceutical composition suitable for vaginal delivery - Google Patents
Pharmaceutical composition suitable for vaginal delivery Download PDFInfo
- Publication number
- WO2021154188A1 WO2021154188A1 PCT/TR2021/050086 TR2021050086W WO2021154188A1 WO 2021154188 A1 WO2021154188 A1 WO 2021154188A1 TR 2021050086 W TR2021050086 W TR 2021050086W WO 2021154188 A1 WO2021154188 A1 WO 2021154188A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- fenticonazole
- composition according
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 88
- 208000034423 Delivery Diseases 0.000 title claims abstract description 25
- 230000009677 vaginal delivery Effects 0.000 title claims abstract description 25
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 claims abstract description 57
- 229960001274 fenticonazole Drugs 0.000 claims abstract description 57
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 47
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 30
- 239000003589 local anesthetic agent Substances 0.000 claims abstract description 24
- 229960005015 local anesthetics Drugs 0.000 claims abstract description 10
- 229940035676 analgesics Drugs 0.000 claims abstract description 9
- 239000000730 antalgic agent Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims description 95
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 36
- 229960005053 tinidazole Drugs 0.000 claims description 36
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical group CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 33
- 229960004194 lidocaine Drugs 0.000 claims description 33
- 229960000282 metronidazole Drugs 0.000 claims description 27
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 27
- 239000012752 auxiliary agent Substances 0.000 claims description 25
- 229960002227 clindamycin Drugs 0.000 claims description 24
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 24
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 22
- 229960004125 ketoconazole Drugs 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 19
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 230000000202 analgesic effect Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 229960001337 fenticonazole nitrate Drugs 0.000 claims description 10
- FJNRUWDGCVDXLU-UHFFFAOYSA-N fenticonazole nitrate Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 FJNRUWDGCVDXLU-UHFFFAOYSA-N 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 7
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 210000004996 female reproductive system Anatomy 0.000 claims description 5
- KPQZUUQMTUIKBP-UHFFFAOYSA-N 1-(2-methyl-5-nitro-1-imidazolyl)-2-propanol Chemical compound CC(O)CN1C(C)=NC=C1[N+]([O-])=O KPQZUUQMTUIKBP-UHFFFAOYSA-N 0.000 claims description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 4
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
- 229960004076 secnidazole Drugs 0.000 claims description 4
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 claims description 3
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical group [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 claims description 3
- IPWKIXLWTCNBKN-UHFFFAOYSA-N Madelen Chemical compound CC1=NC=C([N+]([O-])=O)N1CC(O)CCl IPWKIXLWTCNBKN-UHFFFAOYSA-N 0.000 claims description 3
- 239000004187 Spiramycin Substances 0.000 claims description 3
- 239000004098 Tetracycline Substances 0.000 claims description 3
- 229940023020 acriflavine Drugs 0.000 claims description 3
- 229960000723 ampicillin Drugs 0.000 claims description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 3
- 229960004755 ceftriaxone Drugs 0.000 claims description 3
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 3
- 229960005091 chloramphenicol Drugs 0.000 claims description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 3
- 229960002172 chlorquinaldol Drugs 0.000 claims description 3
- GPTXWRGISTZRIO-UHFFFAOYSA-N chlorquinaldol Chemical compound ClC1=CC(Cl)=C(O)C2=NC(C)=CC=C21 GPTXWRGISTZRIO-UHFFFAOYSA-N 0.000 claims description 3
- 229960001378 dequalinium chloride Drugs 0.000 claims description 3
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 claims description 3
- 229960000691 diiodohydroxyquinoline Drugs 0.000 claims description 3
- UXZFQZANDVDGMM-UHFFFAOYSA-N iodoquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(I)C2=C1 UXZFQZANDVDGMM-UHFFFAOYSA-N 0.000 claims description 3
- MDJFHRLTPRPZLY-UHFFFAOYSA-N nimorazole Chemical compound [O-][N+](=O)C1=CN=CN1CCN1CCOCC1 MDJFHRLTPRPZLY-UHFFFAOYSA-N 0.000 claims description 3
- 229960004918 nimorazole Drugs 0.000 claims description 3
- 229960002313 ornidazole Drugs 0.000 claims description 3
- 229960003342 pivampicillin Drugs 0.000 claims description 3
- ZEMIJUDPLILVNQ-ZXFNITATSA-N pivampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 ZEMIJUDPLILVNQ-ZXFNITATSA-N 0.000 claims description 3
- 229960001294 spiramycin Drugs 0.000 claims description 3
- 235000019372 spiramycin Nutrition 0.000 claims description 3
- 229930191512 spiramycin Natural products 0.000 claims description 3
- 229960002180 tetracycline Drugs 0.000 claims description 3
- 235000019364 tetracycline Nutrition 0.000 claims description 3
- 229930101283 tetracycline Natural products 0.000 claims description 3
- 150000003522 tetracyclines Chemical class 0.000 claims description 3
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 2
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims description 2
- VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical class C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 claims description 2
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims description 2
- 229960001113 butorphanol Drugs 0.000 claims description 2
- 229960004126 codeine Drugs 0.000 claims description 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims description 2
- 229960004193 dextropropoxyphene Drugs 0.000 claims description 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims description 2
- 229960000920 dihydrocodeine Drugs 0.000 claims description 2
- 229960002428 fentanyl Drugs 0.000 claims description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 2
- 229960000240 hydrocodone Drugs 0.000 claims description 2
- 229960003406 levorphanol Drugs 0.000 claims description 2
- 229960001797 methadone Drugs 0.000 claims description 2
- 229960005181 morphine Drugs 0.000 claims description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 2
- 229960004127 naloxone Drugs 0.000 claims description 2
- 229960002085 oxycodone Drugs 0.000 claims description 2
- 229960005118 oxymorphone Drugs 0.000 claims description 2
- 229960000482 pethidine Drugs 0.000 claims description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 239000013543 active substance Substances 0.000 abstract description 3
- 239000003937 drug carrier Substances 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 description 69
- 206010046914 Vaginal infection Diseases 0.000 description 15
- 229940121375 antifungal agent Drugs 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000013112 stability test Methods 0.000 description 11
- 239000003429 antifungal agent Substances 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- -1 pessaries Substances 0.000 description 10
- 230000008570 general process Effects 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 201000008100 Vaginitis Diseases 0.000 description 7
- 229940116364 hard fat Drugs 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 6
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 6
- 208000037009 Vaginitis bacterial Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 4
- 229960003913 econazole Drugs 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 229960004884 fluconazole Drugs 0.000 description 4
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 206010007134 Candida infections Diseases 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 3
- 241000736262 Microbiota Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 241000224527 Trichomonas vaginalis Species 0.000 description 3
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 201000003984 candidiasis Diseases 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960002509 miconazole Drugs 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 244000309462 non-albicans Candida Species 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 239000000003 vaginal tablet Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 2
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 2
- 241000234282 Allium Species 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000207201 Gardnerella vaginalis Species 0.000 description 2
- 206010048461 Genital infection Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 208000001688 Herpes Genitalis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 208000005448 Trichomonas Infections Diseases 0.000 description 2
- 206010044620 Trichomoniasis Diseases 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 239000003911 antiadherent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 208000002479 balanitis Diseases 0.000 description 2
- 229960005274 benzocaine Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 201000004946 genital herpes Diseases 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960004214 tioconazole Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229940093609 tricaprylin Drugs 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 206010046901 vaginal discharge Diseases 0.000 description 2
- 239000006213 vaginal ring Substances 0.000 description 2
- 229940044977 vaginal tablet Drugs 0.000 description 2
- 208000002003 vulvitis Diseases 0.000 description 2
- 208000010484 vulvovaginitis Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- LPEKGGXMPWTOCB-UHFFFAOYSA-N 8beta-(2,3-epoxy-2-methylbutyryloxy)-14-acetoxytithifolin Natural products COC(=O)C(C)O LPEKGGXMPWTOCB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000004746 Atrophic Vaginitis Diseases 0.000 description 1
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241001553290 Euphorbia antisyphilitica Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241001092473 Quillaja Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241001079965 Trichosporon sp. Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010069055 Vulvovaginal pain Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 206010071211 Vulvovaginal swelling Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 150000007980 azole derivatives Chemical class 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229960000400 butamben Drugs 0.000 description 1
- IUWVALYLNVXWKX-UHFFFAOYSA-N butamben Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1 IUWVALYLNVXWKX-UHFFFAOYSA-N 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229940032639 clotrimazole vaginal tablet Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000004574 high-performance concrete Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 239000001726 jatropha manihot extract Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940057867 methyl lactate Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229960005429 sertaconazole Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- AJCUMCNWDGBLSR-UHFFFAOYSA-M sodium;benzoic acid;chloride Chemical compound [Na+].[Cl-].OC(=O)C1=CC=CC=C1 AJCUMCNWDGBLSR-UHFFFAOYSA-M 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940071138 stearyl fumarate Drugs 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229940106668 yucca extract Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Definitions
- the present invention is related to a pharmaceutical composition suitable for vaginal delivery, as well as to the pharmaceutical composition for use in the treatment of infectious diseases in the female reproductive system. More particularly, the invention relates to a pharmaceutical composition comprising fenticonazole with an antibacterial agent, optionally one or more analgesics or local anesthetics agents and a pharmaceutically acceptable excipient and/or auxiliary agent.
- Inflammation of the vagina, or vaginitis is caused by various external and internal factors that alter the vaginal microbiota.
- the most common causes of infectious vaginitis are bacterial vaginosis (BV), vulvovaginal candidiasis (VVC) and trichomonal vaginitis (TV), representing about 90% of cases in women of reproductive age in first level clinics.
- BV bacterial vaginosis
- VVC vulvovaginal candidiasis
- TV trichomonal vaginitis
- a significant percentage of infectious vaginitis occurs in women of all ages, both sexually active and inactive, so many women have had a vaginal infection at least once in their life.
- the healthy vaginal tract of reproductive-aged women is colonized by normal microbiota formed of lactobacilli, which protects against pathogenic bacterial species when present in sufficient numbers.
- Vulvovaginal candidiasis is caused by the overgrowth of yeasts, mainly Candida albicans, which are essentially part of the vaginal flora. Symptoms of vulvovaginal candidiasis include vaginal discharge, itching, pain, and swelling. Although Candida albicans is the most common cause of vulvovaginal candidiasis, non albicans species of Candida, such as Candida glabrata. Candida parapsiiosis, Candida krusei, Candida cerevisiae, Candida tropicalis, Candida iusitaniae, and Trichosporon sp. have increasingly been identified as cause of vulvovaginal candidiasis. Bacterial and Candida infections can coexist. Mixed bacterial and Candida infection occurs in up to about one-fifth of vaginitis cases.
- Trichomonas vaginalis is a flagellate protozoan parasite that causes trichomoniasis, characterized by profuse, yellow-green discharge and vaginal or vulvar irritation.
- vaginal infection treatments include fungicidal and/or antibiotic treatment with azole derivatives.
- Reference and consolidated therapies (either local or systemic) for the treatment of the above conditions are well stablished.
- recommended regimens for bacterial vaginosis include:
- Intravaginal clindamycin cream (2%) once daily for seven days or 300 mg orally twice daily for seven days, or
- Recommended regimens for vaginal candidiasis include:
- First line recommended regimens for the treatment of Trichomonas vaginalis include:
- the increasing incidence of mixed vaginal infections poses a therapeutic challenge because such infections require treatment with multiple drugs.
- European application EP 1712229 A1 discloses oral compositions containing fluconazole, tinidazole or secnidazole for treating vaginal infections of the type Gardnerella vaginalis, Actinomyces, Candida and Trichomonas vaginalis microorganisms present in vaginitis and bacterial vaginosis.
- International application WO 2010026469 A1 discloses a pharmaceutical composition comprising the combination of fluconazole, tinidazole and clindamycin and/or pharmaceutically acceptable salts thereof for treating sexually transmitted infections.
- Application EP 910377 A1 discloses pharmaceutical compositions for topical administration in the treatment of vaginitis comprising a combination of metronidazole and miconazole and one or more local anesthetics such as lidocaine or benzocaine.
- WO 2005087270 A1 discloses a pharmaceutical composition for topical administration comprising terconazole and tinidazole and/or tioconazole
- oral antifungal therapies favor that drug-resistant non-albicans species thrive and spread in the vagina, since a significant amount of drug remains in the gastrointestinal tract, reducing C. albicans and allowing less susceptible non-albicans species to grow.
- such above therapies can be complicated by the emergence of drug-resistant yeasts with variable and even full resistance to conventional prescribed antifungal drugs such as fluconazole, tioconazole, clotrimazole and miconazole.
- the present invention was made in view of the prior art described above, and the object of the present invention is, in a first aspect, to provide a new pharmaceutical composition suitable for vaginal delivery comprising fenticonazole or a pharmaceutically acceptable salt thereof with an antibacterial agent or a pharmaceutically acceptable salt thereof, optionally one or more analgesics or local anesthetics agents, and a pharmaceutically acceptable excipient and/or auxiliary agent.
- the pharmaceutical composition comprises a pharmaceutically effective amount of fenticonazole in combination with a pharmaceutically effective amount of an antibacterial agent and a pharmaceutically acceptable excipient and/or auxiliary agent.
- the pharmaceutical composition comprises a pharmaceutically effective amount of fenticonazole in combination with a pharmaceutically effective amount of an antibacterial agent, a pharmaceutically effective amount of an analgesic or a local anesthetic and a pharmaceutically acceptable excipient and/or auxiliary agent.
- fenticonazole is present as fenticonazole nitrate.
- the antibacterial agent is tinidazole.
- the analgesic or local anesthetic is lidocaine or a pharmaceutically acceptable salt thereof.
- Another aspect of the present invention is to provide a process for preparing a dosage form suitable for vaginal administration comprising the steps of mixing fenticonazole or a pharmaceutically salt thereof in combination with an antibacterial agent and, optionally an analgesic or local anesthetic and a pharmaceutically acceptable excipient and/or auxiliary agent, then, processing the mixture to produce the dosage form.
- Another aspect of the invention is a pharmaceutical composition comprising the combination of the first aspect for use as a medicament for the treatment of infectious diseases or conditions in female reproductive system, such as vulvovaginal infections.
- the word “comprise” encompasses the case of “consisting of”. Additional objects, advantages and features of the invention will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention.
- the following examples and drawings are provided by way of illustration, and they are not intended to be limiting of the present invention.
- the present invention covers all possible combinations of particular and preferred embodiments described herein.
- the present invention is related to an association or combination of fenticonazole and an antibacterial agent, and optionally with an analgesic or local anesthetic, for use in the treatment of infectious diseases conditions in female reproductive system.
- Fenticonazole is an imidazole derivative exhibiting wide spectrum antimycotic activity. It also exerts antibacterial activity, with a spectrum that includes Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermis, Streptococcus spp.) and antiparasitic action against Triconomonas vaginalis and some bacterial species such as Gardnerella vaginalis.
- Fenticonazole is well absorbed through the vaginal wall and it is retained in the outermost layer of the epidermis (stratum corneum) for a long time. This allows its accumulation in the mucosal tissue up to 72 hours, thus maintaining its activity during a long period and delaying consecutive administration. Furthermore, fenticonazole is poorly absorbed at a systemic level.
- the present invention provides, a pharmaceutical composition suitable for vaginal delivery comprising fenticonazole or a pharmaceutically acceptable salt thereof as antifungal agent in combination with antibacterial agent and a pharmaceutically acceptable excipient and/or auxiliary agent.
- fenticonazole is present as fenticonazole nitrate.
- fenticonazole or a pharmaceutically acceptable thereof can be included in the composition of the invention in an amount of about 0.5% to about 70%, for example about 5% to about 60%, or about 10% to about 55%, or about 15% to 50% by weight.
- fenticonazole is present in the composition of the invention in an amount of about 20 to 50% by weight, more preferably of about 25% to 48% by weight.
- the amount of fenticonazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is preferably from about 50 mg to about 2000 mg, more preferably from about 100 mg to about 1500 mg, and even more preferably from about 200 mg to about 1000 mg. In a more preferred embodiment, the amount of fenticonazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is 600 mg.
- the antibacterial agent can comprise any antibacterial known in the art to be useful in treatment of bacterial infections of the vulvovaginal system.
- antibacterials that can be useful include without limitation acriflavine, ampicillin, ceftriaxone, chloramphenicol, chlorquinaldol, ketoconazole, clindamycin, iodoquinol, metronidazole, nimorazole, ornidazole, pivampicillin, secnidazole, spiramycin, tetracycline, tinidazole, dequalinium chloride and pharmaceutically acceptable salts and esters thereof, combinations thereof and the like.
- the antibacterial agent is selected from clindamycin, metronidazole, ketoconazole and tinidazole. In a most preferred embodiment, the antibacterial agent is tinidazole.
- the antibacterial agent can be included in the composition of the invention in an amount of about 0.5% to about 70%, for example about 5% to about 60%, or about 10% to about 55%, or about 15% to 50% by weight.
- fenticonazole is present in the composition of the invention in an amount of about 20 to 50% by weight, more preferably of about 25% to 48% by weight.
- the amount of the antibacterial agent or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention will depend of the activity of the specific antibacterial agent employed and the type of dosage form of the vaginal composition used typically, the amount of antibacterial agent in the pharmaceutical compositions of the invention is preferably from about 10 mg to about 10000 mg, more preferably from about 100 mg to about 5000 mg, still more preferably from about 500 mg to about 3000 mg, and even still more preferably from about 1000 mg to about 2000 mg.
- the antibacterial agent used in the pharmaceutical compositions of the invention is tinidazole or a pharmaceutically acceptable salt thereof.
- the amount of tinidazole or a salt thereof in the pharmaceutical compositions of the invention is from about 200 mg to 5000 mg, more preferably from 500 mg to 3000 mg. In a more preferred embodiment, the amount of tinidazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is from about 1000 mg to about 2000 mg.
- the antibacterial agent used in the pharmaceutical compositions of the invention is metronidazole or a pharmaceutically acceptable salt thereof.
- the amount of metronidazole or a salt thereof in the pharmaceutical compositions of the invention is from about 10 mg to 800 mg, more preferably from 200 mg to 600 mg.
- the amount of metronidazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is from about 300 mg to about 600 mg, preferably of about 500 mg.
- the antibacterial agent used in the pharmaceutical compositions of the invention is ketoconazole or a pharmaceutically acceptable salt thereof.
- the amount of ketoconazole or a salt thereof in the pharmaceutical compositions of the invention is from about 200 mg to 2000 mg, more preferably from 500 mg to 1000 mg. In a more preferred embodiment, the amount of ketoconazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is from about 600 mg to about 900 mg, preferably of about 800 mg.
- the antibacterial agent used in the pharmaceutical compositions of the invention is clindamycin or a pharmaceutically acceptable salt thereof. Typically, the amount of clindamycin or a salt thereof in the pharmaceutical compositions of the invention is from about 50 mg to 200 mg, more preferably from 750 mg to 150 mg. In a more preferred embodiment, the amount of clindamycin or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is from about 90 mg to about 120 mg, preferably of about 100 mg.
- the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising from 200 mg to about 1000 mg fenticonazole or a pharmaceutically acceptable salt thereof as antifungal agent in combination with 500 mg to 3000 mg tinidazole or a pharmaceutically acceptable salt thereof as antibacterial agent and a pharmaceutically acceptable excipient and/or auxiliary agent.
- the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising 600 mg fenticonazole or a pharmaceutically acceptable salt thereof as antifungal agent in combination with 1000 mg to about 2000 mg tinidazole or a pharmaceutically acceptable salt thereof as antibacterial agent and a pharmaceutically acceptable excipient and/or auxiliary agent.
- the relative amount of fenticonazole or a pharmaceutically acceptable salt thereof to antibacterial agent is in the range of from about 10:1 to about 1 :10 on a weight basis. In another embodiment, the relative amounts of fenticonazole or a pharmaceutically acceptable salt thereof to antibacterial agent in the range of from about 7:1 to about 1 :7, preferably from 4:1 to 1 :4. In a further aspect of the invention, the pharmaceutical composition according to the invention can further comprise one or more analgesics or local anesthetics agents.
- analgesics include butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, levorphanol, meperidine, methadone, morphine, naloxone, oxycodone, oxymorphone, pentazocines propoxyphene, pharmaceutically acceptable salts and esters thereof, and combinations thereof.
- Non-limiting examples of local anesthetics include benzocaine, bupivacaine, butamben, chloroprocaine, lidocaine, mepivacaine, pramoxine, prilocaine, procaine, proparacaine, ropivacaine, tetracaine, pharmaceutically acceptable salts and esters thereof, and combinations thereof.
- the local anesthetic is lidocaine or a pharmaceutically acceptable salt thereof.
- the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising fenticonazole or a salt thereof as antifungal agent, one from tinidazole, metronidazole, ketoconazole, clindamycin or salts thereof as antibacterial agent, lidocaine or a salt thereof as analgesic or local anesthetic agent, and a pharmaceutically acceptable excipient and/or auxiliary agent.
- the analgesic or a local anesthetic can be included in a composition of the invention in an amount of about 0.1% to about 20%, for example about 0.5% to about 5%, or about 1% to about 3%, by weight.
- the compositions of the invention can for example contain from about 0.1% to 3.5%, preferably about 2% by weight of lidocaine, and from about 0.1% to 3.0%, preferably about 1.5% by weight of lidocaine.
- the amount of lidocaine or a salt thereof in the pharmaceutical compositions is from about 1 mg to 500 mg, more preferably from 10 mg to 400 mg. In a more preferred embodiment, the amount of lidocaine or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is from about 50 mg to about 200 mg, preferably about 100 mg lidocaine.
- the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising from about 200 mg to about 1000 mg fenticonazole or a salt thereof as antifungal agent in combination with from about 500 mg to about 3000 mg tinidazole or a salt thereof as antibacterial agent and 50 mg to 200 mg lidocaine or a salt thereof as local anesthetic agent a pharmaceutically acceptable excipient and/or auxiliary agent.
- the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising 600 mg fenticonazole or a salt thereof as antifungal agent in combination with 1000 mg to about 2000 mg tinidazole or a salt thereof as antibacterial agent and 75 mg to 150 mg lidocaine or a salt thereof and a pharmaceutically acceptable excipient and/or auxiliary agent.
- the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising 600 mg fenticonazole or a salt thereof as antifungal agent in combination with
- the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising 600 mg fenticonazole or a salt thereof as antifungal agent in combination with 200 mg to about 2000 mg ketoconazole or a salt thereof as antibacterial agent and optionally, 75 mg to 150 mg lidocaine or a salt thereof and a pharmaceutically acceptable excipient and/or auxiliary agent.
- the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising 600 mg fenticonazole or a salt thereof as antifungal agent in combination with 50 mg to about 150 mg clindamycin or a salt thereof as antibacterial agent and optionally, 75 mg to 150 mg lidocaine or a salt thereof and a pharmaceutically acceptable excipient and/or auxiliary agent.
- the pharmaceutical composition suitable for vaginal delivery according to the present invention can be present in a dosage form which includes but it is not limited to tablets, hard or soft gelatin capsules, creams, suppositories, pessaries, foams, ointments, gels, films, tampons, vaginal rings and douches.
- the compositions take the form of pessaries.
- the pharmaceutical composition may be in the form of a pessary containing the pharmaceutical composition suitable for vaginal delivery of the invention and a pessary base.
- the pessary base may be of any conventional material for vaginal administration such as glycerinated glycerin, macrogols (polyethylene glycols), natural, synthetic or semisynthetic hard fats, and fractionated palm kernel oil and mixtures thereof.
- a particularly preferred material is a hard fat such as triglyceride esters.
- the pessary base amounts from about 1% to about 90% by weight of the composition, for example from about 10% to about 70%, or from about 20% to about 60% by weight of the composition.
- the pessary base can also comprise a surfactant to promote dispersal of the active substances and give continuous penetration of the active substances into the mucosa.
- Suitable surfactant agents may be selected from the group consisting of but not limited to benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, docusate sodium, glycine, hypromellose, phospholipids, polysorbates, poloxamer, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, sodium lauryl sulfate, sorbitan esters, tricaprylin or mixtures thereof.
- the surfactant is polysorbate.
- the surfactant agent may be present in an amount from about 0% to 30% by weight, preferably from about 0% to about 20%, more preferably from 0% to 15% based on the total weight of the composition.
- the pessary may include at least one or more further auxiliary agents, to afford the appropriate mechanical and release properties. All such auxiliary agents must be compatible with the other ingredients of the dosage form and not injurious to the human being .
- the auxiliary agent may be selected from the group consisting of diluents, solubilizing agents, emulsifying agents and antioxidants, and/or mixtures thereof.
- Suitable solubilizing agents include corn oil (maize), polyethylene glycol, glycerin, cottonseed oil, dibutyl phthalate, diethyl phthalate, dimethyl ether, dimethyl phthalate, dimethyl sulfoxide, dimethylacetamide, ethyl acetate, ethyl alcohol, ethyl lactate, ethyl oleate, glycofurol, isopropyl alcohol, isopropyl myristate, isopropyl palmitate, light mineral oil, medium-chain triglycerides, methyl lactate, mineral oil, monoethanolamine, octyldodecanol, olive oil, peanut oil, polyoxyl 35 castor oil, propylene carbonate, propylene glycol, pyrrolidone, safflower oil, sesame oil, soybean oil, sunflower oil, triacetin, tricaprylin, triethanolamine, triethyl citrate, triolein, water,
- the solubilizing agent may be present in an amount from about 0% to 80% by weight, preferably from about 0% to about 50%, more preferably from 0% to 30% based on the total weight of the composition.
- Emulsifying agents include lecithin, yucca extract, quillaja bark extract, lanolin, candelilla, carnauba, jojoba, rice bran, beeswax, xanthan gum, quince seed, glyceryl oleate, glyceryl stearate, citrate and mixtures thereof.
- the emulsifying agent may be present in an amount from about 0.05% to 20% by weight, preferably from about 0.1% to about 15%, more preferably from 0.2% to 10% based on the total weight of the composition.
- the emulsifying agent may also be used as solubilizing agent.
- Suitable antioxidant agents include Pythrox LT 10-IP (lecithin, ascorbyl palmitate + tocopherol rch extract, sunflower oil), vitamin E (tocopheryl asetate/tocopheroll), ascorbic acid (vitamin C) or ascorbyl palmitat propolis extract, allium cepae (onion) bulb extract, glycyrrhiza glabra (organic licorice) root extract, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), sodium metabisulfite, propyl gallateand cysteine and mixtures thereof.
- Particularly preferred antioxidants according to the present invention are butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) or mixtures thereof.
- the antioxidant agent may be present in an amount from about 0.005% to 5% by weight, preferably from about 0.01% to about 4%, more preferably from 0.1% to 3% based on the total weight of the composition.
- composition suitable for vaginal delivery of the present invention can be used for other pharmaceutical preparations or dosage forms, for example for tablets, hard or soft gelatin capsules, creams, foams, ointments, gels, films, tampons, vaginal rings and douches.
- the pharmaceutical composition suitable for vaginal delivery of the present invention may be in the form of a cream.
- a conventional cream base may be used, e.g. containing oily or waxy materials such as liquid paraffin, white petroleum or cetyl alcohol, water and one or more surfactants to produce a water- in-oil emulsion.
- the pharmaceutical composition suitable for vaginal delivery of the invention may be in the form of vaginal tablets.
- the tablet comprises a combination of fenticonazole or a pharmaceutically acceptable salt thereof with an antibacterial agent, optionally together with one or more an analgesics or local anesthetics, and at least one pharmaceutically acceptable excipient or carrier, characterized in that the tablet comprises granules comprising the fenticonazole or a pharmaceutically acceptable salt thereof and/or the antibacterial agent and a pharmaceutically acceptable excipient and optionally, extragranular excipients.
- the intragranular and extragranular excipients can comprise one or more of binder, diluent, lubricant and disintegrant agents.
- Suitable diluents include corn starch, microcrystalline cellulose, powdered cellulose, silicified cellulose, lactose monohydrate, anhydrous lactose, mannitol, sorbitol, sucrose, fructose, dextrose, and/or mixtures thereof.
- lactose monohydrate and microcrystalline cellulose are used.
- Diluents may be presents in an amount from about 20% to about 95% by weight, preferably from 35% to 90% by weight, and more preferably from 30 to 85% by weight of the total weight of the composition.
- the dosage form according to the invention comprises a binder.
- the binding agent can be selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methylcellulose, polyvinylpyrrolidone, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, and/or mixtures thereof.
- Binders may be presents in an amount from about 0.5% to about 20% by weight, preferably from 1 % to 18% by weight, and more preferably from 5 to 15% by weight of the total weight of the composition.
- the dosage form according to the invention can also comprise a disintegration agent.
- Disintegrating agents may be selected from the group consisting of low- substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, crospovidone, sodium croscarmellose, and/or mixtures thereof. Preferably sodium croscarmellose is used.
- Disintegrating agents may be present in an amount from about 2% to about 50% by weight, preferably from about 5% to about 45% by weight, and more preferably from 10% to 40% by weight of the total weight of the composition.
- Lubricants and antiadherent agents are excipients that reduce interparticular friction and prevent adhesion of drug particles and improve fluidity of granular or pulverulent compositions.
- Lubricants may be selected from the group consisting of talc, alkaline earth salts of stearic acid, specially magnesium and calcium stearate, stearic acid, glycerin palmitostearate, stearyl fumarate, and/or mixtures thereof.
- the lubricant may be present in an amount from about 0% to 5% by weight, preferably from about 0% to about 3% based on the total weight of the composition.
- the antiadherent agent may be present in an amount from about 0% to 5% by weight, preferably from about 0% to about 3% based on the total weight of the composition.
- the pharmaceutical composition suitable for vaginal delivery of the invention may be in the form of vaginal capsules.
- the vaginal capsule comprises a combination of fenticonazole or a pharmaceutically acceptable salt thereof with an antibacterial agent, optionally together with one or more an analgesics or local anesthetics, and at least one pharmaceutically acceptable excipient or carrier as defined above.
- the excipients can comprise one or more of disintegrant, filler/diluent, binder/adhesive, glidant and lubricant agents using the amounts or percentages stated above.
- Suitable disintegrants may comprise but not limited to sodium starch glycolate, crosscarmellose sodium, crospovidone, aligns, gums, surfactants and the like and mixtures thereof.
- Suitable fillers/diluents may comprise but not limited to dibasic calcium phosphate dihydrate, polysaccharides, primarily microcrystalline cellulose, lactose, mannitol, sugars, sorbitol, sucrose, inorganic salts, primarily calcium salts and the like and mixtures thereof.
- Suitable binders/adhesives may comprise but not limited to polyvinylpyrrolidone (povidone), gelatin, sugars, glucose, natural gums, synthetic celluloses, polymethycrylate, cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose and the like and mixtures thereof.
- polyvinylpyrrolidone povidone
- gelatin sugars
- glucose natural gums
- synthetic celluloses polymethycrylate
- cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose and the like and mixtures thereof.
- Suitable glidants may comprise but not limited to colloidal silicon dioxide, talc, aluminium silicate and the like and mixtures thereof.
- Suitable lubricants may comprise but not limited to magnesium stearate, sodium stearyl fumarate, polyethylene glycol, stearic acid, metal stearates, talc, boric acid, sodium chloride benzoate and acetate, sodium or magnesium lauryl sulfate and the like and mixtures thereof.
- Another aspect of the present invention is, therefore, a process for preparing a dosage form suitable for vaginal administration comprising fenticonazole or a pharmaceutically salt thereof in combination an antibacterial agent, a pharmaceutically acceptable excipient and/or auxiliary agent and optionally, an analgesic or a local anesthetic.
- the process comprises the steps of mixing fenticonazole or a pharmaceutically salt thereof, an antibacterial agent and optionally, an analgesic or a local anesthetic agent with at least one pharmaceutically acceptable excipient and/or auxiliary agent and, then, processing the mixture to produce the dosage form.
- the mixture is processed by filling it into capsules or compressing it to obtain tablets.
- the composition is suitable for administration in a single dose on a single day.
- a preferred embodiment of the invention provides a process for the production of a pessary comprising fenticonazole or a pharmaceutically salt thereof in combination an antibacterial agent, a pharmaceutically acceptable excipient and/or auxiliary agent, and optionally an analgesic or a local anesthetic, comprising the following steps: a) Hard fat is melted b) If present, the surfactant and/or the solubilizing agent is added to the melted fat c) Fenticonazole, the antibacterial agent and optionally the analgesic or a local anesthetic are added to the melted hard fat of step a) or to the mixture obtained in step b) until homogeneous product is obtained d) the final product is filled in an appropriate package
- Another aspect of the invention is the pharmaceutical composition suitable for vaginal delivery comprising: a) fenticonazole or a pharmaceutically acceptable salt thereof and b) an antibacterial agent
- the invention is directed to the pharmaceutical composition suitable for vaginal delivery for use in the treatment of infectious diseases or conditions in female reproductive system, such as vulvovaginal infections
- Vulvovaginal infections include bacterial vaginosis, vulvovaginal candidiasis (both albicans and non-albicans caused infections), trichomonal vaginitis and mixed infections.
- the antibacterial agent is selected from acriflavine, ampicillin, ceftriaxone, chloramphenicol, chlorquinaldol, ketoconazole, clindamycin, iodoquinol, metronidazole, nimorazole, ornidazole, pivampicillin, secnidazole, spiramycin, tetracycline, tinidazole, dequalinium chloride and pharmaceutically acceptable salts and esters thereof and combinations thereof.
- clindamycin, metronidazole, ketoconazole and tinidazole is tinidazole.
- composition of the invention is also considered to be effective in treating any secondary candidial, bacterial and/or trichomonal infections which might result from treatment of such causative agents.
- Vaginal infections due to group B and D streptococcus and the like, infections due to microorganisms causing vulvitis and vulvovaginitis, and other vaginal infections e. g. atrophic vaginitis, allergic or irritant vulvo vaginitis, genital psoriasis (with or without clinically relevant infection), vulvitis due to Lichen sclerosis, etc.
- vaginal infections due to group B and D streptococcus and the like
- infections due to microorganisms causing vulvitis and vulvovaginitis e. g. atrophic vaginitis, allergic or irritant vulvo vaginitis, genital psoriasis (with or without clinically relevant infection), vulvitis
- compositions in accordance with the invention may also find more general use in treating primary and/or secondary genital infections in both men and women, including sexually transmitted infections, e. g. infections due to chlamydia; balanitis; penile dermatitis; herpes genitalis; gonorrhea; etc.
- Another aspect of the invention is directed to the pharmaceutical composition suitable for vaginal delivery for use in the treatment of any secondary Candida, bacterial and/or trichomonas infections which might result from treatment of such causative agents, and in general, in the treatment primary and/or secondary genital infections in both men and women, such us infections due to chlamydia; balanitis; penile dermatitis; herpes genitalis; gonorrhea; etc.
- the antibacterial agent is selected from clindamycin, metronidazole, ketoconazole and tinidazole. In a most preferred embodiment, the antibacterial agent is tinidazole.
- the following antifungal agents could be used in the formulation of the invention: econazole, sertaconazol, or their pharmaceutically acceptable salts or mixtures thereof.
- the amount of econazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is preferably from about 10 mg to about 500 mg, more preferably from about 20 mg to about 400 mg, and even more preferably from about 50 mg to about 300 mg. In a more preferred embodiment, the amount of econazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is 150 mg.
- the amount of sertaconazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is preferably from about 80 mg to 600 mg more preferably from 150 mg to 400 mg and more preferably from 200 mg to 350 mg.
- the pharmaceutical composition according to the present invention may be presented in a pack to providea complete course of treatment.
- Packs comprising at least one formulation containing the pharmaceutical composition according to the present invention are considered to form part of the invention.
- Example 1 A pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the following composition:
- Unit Formula may contain one of Tinidazole, Metronidazole, Ketoconazole or Clindamycin.
- Lidocaine ( w/wo ) means “Unit Formula with or without the presence of Lidocaine”.
- the amount of lidocaine is substituted by hard fat in the above formula General manufacturing process:
- surfactant and/or solubilizing agent(s) and/or is added and mixed (depends on the unit formula)
- a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition: Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 3
- a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition:
- Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 4
- a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition: Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 5
- a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition: Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 6
- a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition: Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 7
- a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition: Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 8
- a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition:
- Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 9
- a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition: Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 10
- a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition:
- a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of vaginal tablet is prepared according to the following composition:
- PVP polysorbate and ascorbic acid is solved in a proper solvent or solvent mixture as granulation solution.
- APIs, MCC and crospovidone are mixed to obtain homogeneous powder and granulate with granulation solution. 3. These granules are sieved and dried.
- a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of vaginal capsule is prepared according to the following composition: Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin
- APIs, lactose and croscarmellose sodium, sodium starch glycolate, HPC, and, tartaric acid are sived and mixed to obtain homogenious powder.
- Colloidal silicone dioxide are added by sieving and mixed.
- magnesium stearate is added by sieving and mixed for a short time.
- Stability studies were performed in the pharmaceutical composition according to the present invention. Particularly, stability studies were performed by using the pharmaceutical composition of the present invention with and without Lidocaine.
- PIPLC analytical test methods for fenticonazole nitrate, tinidazoie and lidocaine (w/wo) ovule product are detailed below.
- a detailed information for Impurities A to D of Fenticonazole Nitrate can be found at the European Pharmacopeia 10.0, 07/2014:1211 , corrected 10.0, p. 2622-2624, which is incorporated herein by reference.
- a detailed information for Impurities A and B of Tinidazole can be found at the European Pharmacopeia 10.0, 01/2017:1051 , p. 4048-4049, which is incorporated herein by reference.
- STABILITY ASSAYS for Example 2 without lidocaine Stability of formulation according to example 2 without lidocaine (the amount of lidocaine is substituted by the same amount of hard fat) comprising fenticonazole nitrate and tinidazole as active ingredients was tested at different conditions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21748063.1A EP4096655A4 (en) | 2020-01-31 | 2021-01-29 | Pharmaceutical composition suitable for vaginal delivery |
BR112022015112A BR112022015112A2 (en) | 2020-01-31 | 2021-01-29 | SUITABLE PHARMACEUTICAL COMPOSITION FOR VAGINAL RELEASE AND USE THEREOF |
MX2022009303A MX2022009303A (en) | 2020-01-31 | 2021-01-29 | Pharmaceutical composition suitable for vaginal delivery. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR202001511 | 2020-01-31 | ||
TR2020/01511 | 2020-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021154188A1 true WO2021154188A1 (en) | 2021-08-05 |
Family
ID=77079220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2021/050086 WO2021154188A1 (en) | 2020-01-31 | 2021-01-29 | Pharmaceutical composition suitable for vaginal delivery |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4096655A4 (en) |
BR (1) | BR112022015112A2 (en) |
EC (1) | ECSP22067445A (en) |
MX (1) | MX2022009303A (en) |
WO (1) | WO2021154188A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005087270A1 (en) * | 2004-03-10 | 2005-09-22 | Edko Trading And Representation Co. Ltd. | Anti-vaginitis compositions comprising a triazole |
WO2006060462A1 (en) * | 2004-12-01 | 2006-06-08 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods of treating irritation and kit therefor |
RU2016138895A (en) * | 2016-10-03 | 2018-04-04 | Михаил Лукич Ткаченко | Eutectic type antifungal composition (options) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103690476A (en) * | 2014-01-06 | 2014-04-02 | 海南海力制药有限公司 | Micronized fenticonazole nitrate preparation composition and preparation method thereof |
TR201413590A3 (en) * | 2014-11-17 | 2021-06-21 | Pharmaceutical composition for use in treatment of vaginal infection comprises active substance or its derivative exhibiting antiprotozoal activity, and local anesthetic agent | |
WO2016100203A1 (en) * | 2014-12-20 | 2016-06-23 | Gregg John Malcolm Hall | Antimicrobial drug synthesis and therapeutic compositions |
CN108079098A (en) * | 2018-02-28 | 2018-05-29 | 翔宇药业股份有限公司 | Pharmaceutical preparation of anti-fungal infection and preparation method thereof |
CN108210448A (en) * | 2018-04-09 | 2018-06-29 | 翔宇药业股份有限公司 | Fenticonazole nitrate suppository and its application |
-
2021
- 2021-01-29 BR BR112022015112A patent/BR112022015112A2/en unknown
- 2021-01-29 WO PCT/TR2021/050086 patent/WO2021154188A1/en unknown
- 2021-01-29 MX MX2022009303A patent/MX2022009303A/en unknown
- 2021-01-29 EP EP21748063.1A patent/EP4096655A4/en active Pending
-
2022
- 2022-08-26 EC ECSENADI202267445A patent/ECSP22067445A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005087270A1 (en) * | 2004-03-10 | 2005-09-22 | Edko Trading And Representation Co. Ltd. | Anti-vaginitis compositions comprising a triazole |
WO2006060462A1 (en) * | 2004-12-01 | 2006-06-08 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods of treating irritation and kit therefor |
RU2016138895A (en) * | 2016-10-03 | 2018-04-04 | Михаил Лукич Ткаченко | Eutectic type antifungal composition (options) |
Non-Patent Citations (1)
Title |
---|
See also references of EP4096655A4 * |
Also Published As
Publication number | Publication date |
---|---|
ECSP22067445A (en) | 2022-11-30 |
MX2022009303A (en) | 2022-09-19 |
EP4096655A1 (en) | 2022-12-07 |
EP4096655A4 (en) | 2024-02-28 |
BR112022015112A2 (en) | 2022-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6259490B2 (en) | Oral dosage form of bendamustine and its therapeutic use | |
US20060140990A1 (en) | Composition for topical treatment of mixed vaginal infections | |
AU2011219452B2 (en) | Veterinary compositions | |
CN102946869A (en) | Immediate release formulations and dosage forms of gamma-hydroxybutyrate | |
CA2766884C (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application | |
JP6276756B2 (en) | 1,1-dimethylethyl [(1S) -1-{[(2S, 4R) -4- (7-chloro-4methoxyisoquinolin-1-yloxy) -2-({(1R, 2S) -1- [ Solubilized capsule formulation of (cyclopropylsulfonyl) carbamoyl] -2-ethenylcyclopropyl} carbamoyl) pyrrolidin-1-yl] carbonyl} -2,2-dimethylpropyl] carbamate | |
CA2182004C (en) | Film coated tablet of paracetamol and domperidone | |
KR20080083190A (en) | Drug delivery system for bioadhesion to a vulvovaginal surface | |
TW202143997A (en) | Oral pharmaceutical composition | |
WO2021154188A1 (en) | Pharmaceutical composition suitable for vaginal delivery | |
US20060002997A1 (en) | Nitrofurantoin controlled release dosage form | |
KR101653424B1 (en) | Pharmaceutical composition for use in treating sexually transmitted infections | |
WO2021011622A1 (en) | Secnidazole soft gelatin capsule and methods and uses thereof | |
CN1771989A (en) | Compound prepn for treating women's inflammation | |
AU2014208223A1 (en) | Veterinary compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21748063 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022015112 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021748063 Country of ref document: EP Effective date: 20220831 |
|
ENP | Entry into the national phase |
Ref document number: 112022015112 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220729 |